Login / Signup

The co-crystal structure of Cbl-b and a small-molecule inhibitor reveals the mechanism of Cbl-b inhibition.

Serah W KimaniSumera PerveenMagdalena SzewezykHong ZengAiping DongFengling LiPegah GhiabiYanjun LiIrene ChauCheryl H ArrowsmithDalia Barsyte-LovejoyVijayaratnam SanthakumarMasoud VedadiLevon Halabelian
Published in: Communications biology (2023)
Cbl-b is a RING-type E3 ubiquitin ligase that is expressed in several immune cell lineages, where it negatively regulates the activity of immune cells. Cbl-b has specifically been identified as an attractive target for cancer immunotherapy due to its role in promoting an immunosuppressive tumor environment. A Cbl-b inhibitor, Nx-1607, is currently in phase I clinical trials for advanced solid tumor malignancies. Using a suite of biophysical and cellular assays, we confirm potent binding of C7683 (an analogue of Nx-1607) to the full-length Cbl-b and its N-terminal fragment containing the TKBD-LHR-RING domains. To further elucidate its mechanism of inhibition, we determined the co-crystal structure of Cbl-b with C7683, revealing the compound's interaction with both the TKBD and LHR, but not the RING domain. Here, we provide structural insights into a novel mechanism of Cbl-b inhibition by a small-molecule inhibitor that locks the protein in an inactive conformation by acting as an intramolecular glue.
Keyphrases
  • small molecule
  • clinical trial
  • protein protein
  • high throughput
  • transcription factor
  • binding protein
  • amino acid
  • double blind